Chronic Inflammatory Demyelinating Polyneuropathy Market Expected to Grow Through 2036 on Advancing Clinical Research

Industry
โดย PR Newswire·Read original
Summary · why it matters

The chronic inflammatory demyelinating polyneuropathy treatment market is projected to grow positively by 2036 across leading markets, driven by an expanding diagnosed patient population, improved disease awareness, and the anticipated introduction of novel mechanism-based therapies. The United States accounted for the largest market size in 2025 compared with the EU4 countries, the United Kingdom, and Japan. Key companies advancing new treatments include Sanofi, Immunovant, argenx, Nuvig Therapeutics, Dianthus Therapeutics, and Takeda, with promising pipeline therapies such as Riliprubart, Batoclimab, Empasiprubart, NVG-2089, DNTH103, TAK-881, and TAK-411. The prevalence of CIDP is estimated at around 5 to 7 cases per 100,000 individuals in the UK, and the market is seeing increased demand for targeted and long-acting therapies including subcutaneous immunoglobulin formulations and FcRn inhibitors.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 3 stocks
Dianthus Therapeutics Inc.
DNTH
▲ PositiveDemandrelevance

Dianthus Therapeutics is developing DNTH103, a promising pipeline therapy for CIDP, and the market growth driven by expanding patient population and awareness increases potential demand.

Immunovant Inc
IMVT
▲ PositiveDemandrelevance

Immunovant is developing Batoclimab for CIDP, and the projected market growth and demand for targeted therapies benefit its pipeline.

Takeda Pharmaceutical Co. Ltd.
4502
▲ PositiveDemandrelevance

Takeda has pipeline candidates TAK-881 and TAK-411 for CIDP, and the growing market increases opportunity for these therapies.

Health Care▲ · 2 stocks
argenx NV ADR
ARGX
▲ PositiveDemandrelevance

argenx is advancing Empasiprubart for CIDP, and the expanding market and need for novel therapies support its potential.

Sanofi SA
SAN
▲ PositiveDemandrelevance

Sanofi is developing Riliprubart for CIDP, and the market growth and demand for new treatments enhance its prospects.

Theme Impact 1

Off-coverage companies 1

Nuvig TherapeuticsPrivate▲ Positive
Demandrelevance

Nuvig Therapeutics is developing NVG-2089, a pipeline therapy for CIDP, and the article highlights growing patient population and demand for targeted therapies.

Related news

▲

Bristol Myers Sotyktu Shows Two-Year PsA Efficacy in POETYK Study

Bristol Myers Squibb announced positive two-year results from the late-stage POETYK PsA-2 study of Sotyktu, or deucravacitinib, including its open-label extension. Among patients entering the extension, clinical responses improved from week 16 through week 52 and were sustained through week 104, with robust results across ACR20/50/70 and Minimal Disease Activity in both continuous Sotyktu patients and those who switched from placebo at week 16. The safety profile remained consistent through week 104 with no new safety signals; adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively. Sotyktu, an oral selective tyrosine kinase 2 inhibitor approved in the United States and numerous other countries for moderate-to-severe plaque psoriasis and active psoriatic arthritis, generated $156 million in first-half 2026 revenues, up 24% year over year. Data from the POETYK SLE-1 and SLE-2 studies in systemic lupus erythematosus are expected later in 2026, while Amgen's Otezla and Takeda's investigational zasocitinib, whose new drug application the FDA recently accepted for plaque psoriasis, remain competitive threats.
BMY ▲
Biotech & Genomic Medicine ▲
Zacks Investment Research·1dRead more →
3

Novo's Denecimig Wins CHMP Backing for Hemophilia A in EU

Novo Nordisk said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of denecimig, also known as Mim8, for the treatment of hemophilia A, with or without inhibitors, in adults and children. Denecimig is a next-generation factor VIIIa mimetic bispecific antibody given subcutaneously as routine prophylaxis, with flexible dosing that includes once-monthly, every-two-week and weekly administration, and it is being developed as a prefilled pen. Novo expects to launch the drug in the first European countries in the fourth quarter of 2026 under the brand name Frehemgo, followed by a broader rollout across the European Union beginning in early 2027. The positive opinion is supported by data from the FRONTIER clinical program, which comprises five studies evaluating denecimig as a prophylactic treatment for hemophilia A across pediatric and adult populations, with or without inhibitors; in the FRONTIER 2 study denecimig significantly reduced annualized bleeding rates, results in children younger than 12 in FRONTIER 3 were consistent with those in adolescents and adults, and in FRONTIER 5 no new safety concerns were identified when participants switched directly from emicizumab to denecimig. The candidate is also under regulatory review in the United States for routine prophylaxis in adults and children with hemophilia A, with or without inhibitors, after Novo submitted a biologics license application to the FDA in September 2025. Novo already markets Alhemo for hemophilia A and B in patients with or without inhibitors.
ACIUALDXNOV.XETRAPGEN
Biotech & Genomic Medicine ▲
Zacks Investment Research·1dRead more →
▼impact 4

Trump to Announce Most Favored Nation Drug Pricing for Medicaid in All 50 States

President Trump will announce on Friday that Medicaid beneficiaries in all 50 states will receive Most Favored Nation pricing discounts on some prescription drugs. The White House Council of Economic Advisers projects the move will generate $27.6B in savings for state governments and $36.6B for the federal government over 10 years, according to Semafor, which broke the news. Trump is also scheduled to meet today with the governors of Arkansas, Mississippi, and South Dakota to discuss progress on lowering drug prices. Separately, an AARP Public Policy Institute report released in August found that applying MFN pricing to the top 10 drugs by Medicare Part D and Part B spending in 2025 would cut Medicare spending on those drugs from $273B to $76B between 2029 and 2033.
ABBVJNJLLYMRKNOV.XETRAPFE+1
Biotech & Genomic Medicine ▼
Seeking Alpha·1dRead more →
© 2026 MarketDXNews